Purpose According to different ACE genotype with essential hypertension patients, to investigate responses of patients with different ACE genotype to the treatment of angiotensin-converting enzyme inhibitor (ACEI) ,in order to direct clinic useing drug.Method The materials for the present study were obtained from 99 healthy volunteer and 80hypertensive patients,ACE gene polymorphsim was examined by the polymerase chain reaction (PCR) method and the patients was classified as Ⅱ, ID and DD genotype. According to ACE gene I/D polymorphsim 80 patients with hypertension were divided in Ⅱ (n=22) ,ID (n=28)and DD (n=30) groups. All patients were treated with captoprii for 4 weeks.24 hour ambulatory blood pressure monitory was evaluated before and after treatment.Results The frequency of the Ⅱ genotype was 23％ (23), the ID genotype was 47％ (46) and the DD genotype was 31％ (30) in controls. The frequency of the Ⅱ genotype was 28％ (22) ,the ID genotype was 35％ (28) and the DD genotype was35％ (28) in hypertensive patients.These results suggest that there is no significant difference in the distribution of ACE genotypes between hypertensive patients and controls (P＞0.05). Captopril was administered for 4 weeks to 80 essential hypertensives, Validity was 73％ in Ⅱ (n=16) , Validity was 79％ in ID (n=22) ,Validity was 83％ in DD (n=25) . There is no significant difference in the distribution of ACE genotypes between effective group and no effective group (P＞0.05) .Conclusion These results suggest that there is no significant difference in the distribution of ACE genotypes between hypertensive patients and controls, essential hypertension was not associated with ACE gene I/D polymorphsim. No significant association between the ACE gene I/D polymorphsim and the response of BP reduction by ACEI was found. These results suggest that ACE gene I/D polymorphsim do not associate to the blood pressure lowing response to antihypertensive treatment with ACE inhibition (captopril) .
展开▼
